The purpose of the duplicate, randomized, double-blind KALOS and LOGOS trials was to examine Breztri as a possible asthma medication.
In more than three decades, the first possible therapy breakthrough for BCG-naïve, high-risk non-muscle invasive bladder cancer has been the combination of BCG and sasanlimab, a subcutaneously administered PD-1 inhibitor.
In contrast to conventional cardiac ablation techniques, PFA therapy targets specific cardiac tissue regions with high-energy electrical pulses that result in irregular heartbeats.
CENTERSTONE is the first worldwide phase III trial that shows how effective an antiviral medication is at slowing the spread of a respiratory virus.
The trial achieved its main goal with a statistically significant and clinically relevant improvement in PFS.
In a Phase 3 trial, orforglipron, the first small molecule GLP-1, successfully reduced A1C by an average of 1.3% to 1.6% across dosages.
All nine subjects of phase 1 injected without any serious adverse events.
Tolebrutinib was generally well tolerated by all subjects across all study arms.
IMDELLTRA’s safety profile was consistent with the recognized profile. Detailed DeLLphi-304 results will be presented at an upcoming medical congress.
Novo Nordisk presented the full results of STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial that looked at the effects of once-weekly injectable Ozempic®.
